Photodynamic therapy in melanoma - An update

Journal of Physiology and Pharmacology

Volumn 63, Issue 2, 2012, Pages 109-118

  Baldea, I ^a   Filip, A G ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Caspase; Immune response; Melanin; Melanoma; Photodynamic therapy; Superoxide anion

Indexed keywords

5,10 DI (4 ACETAMIDOPHENYL) 15,20 DI (4 N METHYLPYRIDYL)PORPHYRIN; 5,10,15,20 TETRAKIS(2 CHLORO 5 SULFOPHENYL)BACTERIOCHLORIN; AMINOLEVULINIC ACID; CANCER VACCINE; CHLORIN DERIVATIVE; CHLOROALUMINUM SULFONATED PHTHALOCYANINE; CLORIN E(6); GAMMA INULIN; HYDROXYL RADICAL; INULIN; LUTETIUM TEXAPHYRIN; MELANIN; MESO TETRA 4 N METHYLPYRIDYL PORPHYRIN IODIDE; METALLOPHTHALOCYANINE; PHOTOFRIN; PHOTOFRIN II; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; SILICON NAPHTHALOCYANINE LIPOSOME; SILICON PHTHALOCYANINE BICHOLESTERYLOXY DERIVATIVE; SINGLET OXYGEN; SUPEROXIDE; TEMOPORFIN; TETRASULFOPHTHALOCYANINE ZINC; UNCLASSIFIED DRUG; VERTEPORFIN;

AMELANOTIC MELANOMA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BEIDEGROM MELANOMA; CANCER INHIBITION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CHOROID MELANOMA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CUTANEOUS MELANOMA; CYTOKINE RELEASE; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; LIGHT DAMAGE; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA METASTASIS; MELANOSOME; MESOTHELIOMA; METASTATIC MELANOMA; MICROMETASTASIS; NONHUMAN; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; REVIEW; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; SURVIVAL TIME; TUMOR CELL DESTRUCTION; TUMOR NECROSIS; TUMOR VASCULARIZATION; UVEA MELANOMA;

ANIMALS; CELL DEATH; EYE NEOPLASMS; HUMANS; MELANINS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84861862161     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. NCCN Guidelines Version 2.2012 Melanoma. 2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed Sept 21, 2011.
3. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500-507.
4. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumor-directed treatment for melanoma. Br J Dermatol 2006; 155: 1287-1292.
5. Ion RM. New trends in photodynamic therapy-review. In: Aspects of Photodynamic Medicine. Biomedicine Engineering Acta. H. Podbielska, A. Sieron, W. Strek, (eds), Wroclaw, Poland 2008; pp 123-159.
6. Ion RM, Derivative UV-Vis spectrophotometry for porphyrins interactions in photodynamic therapy. Anal Lett 2010; 43: 1277-1286.
7. Garland MJ, Cassidy CM, Woolfson D, Donnelly RF. Designing photosensitizers for photodynamic therapy: strategies, challenges and promising developments. Future Med Chem 2009; 1: 667-691.
8. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumor immunity. Nat Rev Cancer 2006; 6: 535-545.
9. Mroz P, Huang Y Y, Szokalska A, et al. Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J 2010; 24: 3160-1370.
10. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 2005; 52: 339-352.
11. Skidan I, Dholakia P, Torchilin V. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J Drug Target 2008; 16: 486-493.
12. Dabrowski JM, Pereira MM, Arnaut LG, et al. Synthesis, photophysical studies and anticancer activity of new halogenated water-soluble porphyrin. Photochem Photobiol 2007; 83: 897-903.
13. Krestyn E, Kolarova H, Bajgar R, Tomankova K. Photodynamic properties of ZnTPPS(4), ClAlPcS(2) and ALA in human melanoma G361 cells. Toxicol In Vitro 2010; 24: 286-291.
14. Hao E, Friso E, Miotto G, et al. Synthesis and biological investigations of tetrakis(p-carboranylthio-tetrafluorophenyl) chlorin (TPFC). Org Biomol Chem 2008; 6: 3732-3740.
15. Thibaut S, Bourre L, Hernot D, Rousset N, Lajat Y, Patrice T. Effects of BAPTA-AM, forskolin, DSF and Z.VAD.fmk on PDT-induced apoptosis and m-THPC phototoxicity on B16 cells. Apoptosis 2002; 7: 99-106.
16. Schuitmaker JJ, van Best JA, van Delft JL, Dubbelman TM, Oosterhuis JA, de Wolff-Rouendaal D. Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results. Invest Ophthalmol Vis Sci 1990; 31: 1444-1450.
17. Dabrowski JM, Arnaut LG, Pereira MM, Urbanska K, Stochel G. Improved biodistribution, pharmacokinetics and photodynamic efficacy using a new photostable sulfonamide bacteriochlorin. Med Chem Commun 2012; 3: 502-505.
18. Kolarova H, Nevrelova P, Bajgar R, Jirova D, Kejlova K, Strnad M. In vitro photodynamic therapy on melanoma cell lines with phthalocyanine. Toxicol In Vitro 2007; 21: 249-253.
19. Barge J, Decreau R, Julliard M, et al. Killing efficacy of a new silicon phtalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mitochondrion-mediated apoptosis. Exp Dermatol 2004; 13: 33-44.
20. Delfian M, Richert C, Gamarra E, et al. Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers. Int J Cancer 1996; 65: 246-248.
21. Davids LM, Kleemann B, Kacerovska D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008; 91: 67-76.
22. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma. Photochem Photobiol 1996; 64: 375-381.
23. Rosenbach-Belkin V, Chen L, Fiedor L, et al. Serine conjugates of chlorophyll and bacteriochlorophyll: photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Photochem Photobiol 1996; 64: 174-181.
24. Calzavara-Pinton P G, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 2: Clinical results. J Eur Acad Dermatol Venereol 2006; 21: 439-351.
25. Abels C, Fritsch C, Bolsen K, et al. Photodynamic therapy with 5-aminolaevulinic acid-induced porphyrins of an amelanotic melanoma in vivo. J Photochem Photobiol B 1997; 40: 76-83.
26. Robertson CA, Abrahamse H. The in vitro PDT efficacy of a novel metallophthalocyanine (MPc) derivative and established 5-ALA photosensitizing dyes against human metastatic melanoma cells. Lasers Surg Med 2010; 42: 766-776.
27. Moan J, Berg K.The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53: 549-553.
28. Golab J, Nowis D, Skrzycki M, et al. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem 2003; 278: 407-414.
29. Clichici S, Filip A, Daicoviciu D, et al. The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung 2010; 97: 41-51.
30. Daicoviciu D, Filip A, Ion RM, Clichici S, Decea N, Muresan A. Oxidative photodamage induced by photodynamic therapy with methoxyphenyl porphyrin derivatives in tumour-bearing rats. Folia Biol Prague 2010; 56: 12-19.
31. Woods JA, Traynor NJ, Brancaleon L, Moseley H. The effect of photofrin on DNA strand breaks and base oxidation in HaCaT keratinocytes: a comet assay study. Photochem Photobiol 2004; 79: 105-113.
32. Kiesslich T, Plaetzer K, Oberdanner CB, Berlanda J, Obermair FJ, Krammer B. Differential effects of glucose deprivation on the cellular sensitivity towards photodynamic treatment-based production of reactive oxygen species and apoptosis-induction. FEBS Lett 2005; 579: 185-190.
33. Barberi-Heyob M, Vedrine PO, Merlin JL, et al. Wild type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis. Int J Oncol 2004; 24: 951-958.
34. Gupta S, Dwarakanath BS, Muralidhar K, Jain V. Role of apoptosis in photodynamic sensitivity of human tumour cell lines. Ind J Exp Biol 2003; 41: 33-40.
35. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430.
36. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002; 1: 1-21.
37. Susan M, Baldea I, Senila S, et al. Photodamaging effects of porphyrins and chitosan on primary human keratinocytes and carcinoma cell cultures, Int J Dermatol 2011; 50: 280-286.
38. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704: 59-86.
39. Wyld L, Reed MW, Brown NJ. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer 2001; 84: 1384-1386.
40. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84: 131-179.
41. Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009; 9: 3.
42. Filip AG, Clichici S, Daicoviciu D, et al. Possible in vivo mechanisms involved in photodynamic therapy using tetrapyrrolic macrocycles. Braz J Med Biol Res 2011; 44: 53-61.
43. Chan W-H. Photodynamic treatment induces an apoptotic pathway involving calcium, nitric oxide, p53, p21-activated kinase 2, and c-Jun N-terminal kinase and inactivates survival signal in human umbilical vein endothelial cells. Int J Mol Sci 2011; 12: 1041-1059.
44. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-8607.
45. Scott FL, Stec B, Pop C, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457: 1019-1022.
46. Tong Z, Singh G, Rainbow AJ. The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy. Photochem Photobiol 2000; 71: 201-210.
47. Szurko A, Kramer-Marek G, Widel M, Ratuszna A, Habdas J, Kus P. Photodynamic effects of two water soluble porphyrins evaluated on human malignant melanoma cells in vitro. Acta Biochim Pol 2003; 50: 1165-1174.
48. Saczko J, Kulbacka J, Chwilkowska A, et al. The influence of photodynamic therapy on apoptosis in human melanoma cell line. Folia Histochem Cytobiol 2005; 43: 129-132.
49. Ickowicz Schwartz D, Gozlan Y, Greenbaum L, Babushkina T, Katcoff DJ, Malik Z. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Br J Cancer 2004; 90: 1833-1841.
50. Maduray K, Karsten A, Odhav B, Nyokong T. In vitro toxicity testing of zinc tetrasulfophthalocyanines in fibroblast and keratinocyte cells for the treatment of melanoma cancer by photodynamic therapy. J Photochem Photobiol B 2011; 103: 98-104.
51. Otake E, Sakuma S, Torii K, et al. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. Photochem Photobiol 2010; 86: 1356-1363.
52. Young LH, Howard MA, Hu LK, Kim RY, Gragoudas ES. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996; 114: 186-192.
53. Haddad R, Blumenfeld A, Siegal A, et al. In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma. Ann Surg Oncol 1998; 5: 241-247.
54. Dabrowski JM, Krzykawska M, Arnaut LG, et al. Tissue uptake study and photodynamic therapy of melanoma-bearing mice with a nontoxic, effective chlorin. ChemMedChem 2011; 6: 1715-1726.
55. Dabrowski JM, Urbanska K, Arnaut LG, et al. Biodistribution and photodynamic efficacy of a water-soluble, stable, halogenated bacteriochlorin against melanoma. ChemMedChem 2011; 6: 465-475.
56. Ozler SA, Nelson JS, Liggett PE, de Queiroz JM Jr, Berns MW. Photodynamic therapy of experimental subchoroidal melanoma using chloroaluminum sulfonated phthalocyanine. Arch Ophthalmol 1992; 110: 555-561.
57. Hu L, Wu X, Song Y, Young LH, Gragoudas ES. Photodynamic therapy of pigmented choroidal melanomas in rabbits. Zhonghua Yan Ke Za Zhi 2002; 38: 491-494.
58. Haddad R, Kaplan O, Greenberg R, Siegal A, Skornick Y, Kashtan H. Photodynamic therapy of murine colon cancer and melanoma using systemic aminolevulinic acid as a photosensitizer. Int J Surg Investig 2000; 2: 171-178.
59. Tammela T, Saaristo A, Holopainen T, et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011; 3: 69-80.
60. Panagopoulos JA, Svitra PP, Puliafito CA, Gragoudas ES. Photodynamic therapy for experimental intraocular melanoma using chloroaluminum sulfonated phthalocyanine. Arch Ophthalmol 1989; 107: 886-890.
61. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003; 135: 898-899.
62. Donaldson MJ, Lim L, Harper CA, Mackenzie JG, Campbell W. Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin Experiment Ophthalmol 2005; 33: 548-549.
63. Soucek P, Cihelkova I. Photodynamic therapy with verteporfin in subfoveal amelanotic choroidal melanoma (a controlled case). Neuroendocrinol Lett 2006; 27: 145-148.
64. Sheleg S V, Zhavrid EA, Khodina T V, et al. Photodynamic therapy with chlorin e(6) for skin metastases of melanoma. Photodermatol Photoimmunol Photomed 2004; 20: 21-26.
65. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 2007; 21: 976-994.
66. Baldea I, Mocan T, Cosgarea R. The role of ultraviolet radiation and tyrosine stimulated melanogenesis in the induction of oxidative stress alterations in fair skin melanocytes. Exp Oncol 2009; 31: 200-208.
67. Liu JJ, Fisher DE. Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell Melanoma Res 2010; 23: 741-745.
68. Baldea I. Melanocyte pigmentation - friend or foe on the route to melanoma. In: Breakthroughs in Melanoma Research. Y. Tanaka (ed), Rijeka, Croatia, InTech, 2011, pp. 183-217.
69. Riley PA. Melanogenesis and melanoma. Pigment Cell Res 2003; 16: 548-552.
70. Simon JD, Peles D, Wakamatsu K, Ito S. Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function. Pigment Cell Melanoma Res 2009; 22: 563-579.
71. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005; 52: 743-775.
72. Nelson JS, McCullough JL, Berns MW. Photodynamic therapy of human malignant melanoma xenografts in athymic nude mice. J Natl Cancer Inst 1988; 80: 56-60.
73. Chen K G, Valencia JC, Gillet J-P, Hearing VJ, Gottesman MM. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res 2009; 22: 740-749.
74. Chen KG, Leapman RD, Zhang G, et al. Influence of the melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst 2009; 101: 1259-1271.
75. Jaszewska E, Kosmider A, Kiss AK, Naruszewicz M. Oenothera Paradoxa defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine. J Physiol Pharmacol 2010; 61: 637-643.
76. Liu Y, Hong L, Wakamatsu K, et al. Comparison of structural and chemical properties of black and red human hair melanosomes. Photochem Photobiol 2005; 81: 135-144.
77. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 2009; 124: 1470-1477.
78. Brozyna AA, Van Middlesworth L, Slominski AT. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. Int J Cancer 2008; 123: 1448-1456.
79. Sharma KV, Bowers N, Davids LM. Photodynamic therapy-induced killing is enhanced in depigmented metastatic melanoma cells. Cell Biol Int 2011; 35: 939-944.
80. Woodburn KW, Fan Q, Kessel D, Luo Y, Young SW. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. J Invest Dermatol 1998; 110: 746-751.
81. Busetti A, Soncin M, Jori G, Rodgers MA. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br J Cancer 1999; 79: 821-824.
82. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 2006; 16: 279-305.
83. Davids LM, Kleemann B. Combating melanoma: the use of photodynamic therapy as a novel, adjuvant therapeutic tool. Cancer Treat Rev 2011; 37: 465-475.
84. Olivo M, Chin W. Perylenequinones in photodynamic therapy: cellular versus vascular response. J Environ Pathol Toxicol Oncol 2006; 25: 223-237.
85. Bhuvaneswari R, Gan YY, Lucky SS, et al. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer 2008, 7: 56.
86. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006; 38: 516-521.
87. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006; 66: 10953-10958.
88. Ferrario A, Fisher AM, Rucker N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005; 65: 9473-9478.
89. Mazor O, Brandis A, Plaks V, et al. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 2005; 81: 342-351.
90. Brezillon S, Zeltz C, Schneider L, et al. Lumican inhibits B16F1 melanoma cell lung metastasis J Physiol Pharmacol 2009, 60(Suppl 4): 15-22.
91. Offner FA, Ensinger C, Schiefer J, et al. Tumour-cell-endothelial interactions: free radicals are mediators of melanoma-induced endothelial cell damage Virchows Arch 1996; 428: 99-106.
92. Fonsatti E, Lamaj E, Coral S, et al. In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. Cancer Immunol Immunother 1999; 48: 132-138.
93. Li J, Li G. Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res 2010; 70: 10445-10453.
94. Li Z, Huang P, Lin J, et al. Arginine-glycine-aspartic acid-conjugated dendrimer-modified quantum dots for targeting and imaging melanoma. J Nanosci Nanotechnol 2010; 10: 4859-4867.
95. Roy S, Reddy BS, Sudhakar G, Kumar JM, Banerjee R. 17β-estradiol-linked nitro-L-arginine as simultaneous inducer of apoptosis in melanoma and tumor-angiogenic vascular endothelial cells. Mol Pharm 2011; 8: 350-359.
96. Liu W, Wu S. The roles of Akt and NOSs in regulation of VLA-4-mediated melanoma cell adhesion to endothelial VCAM-1 after UVB-irradiation. Arch Biochem Biophys 2011; 508: 192-197.
97. Yang Z, Lu X, Frazier DL, Panjehpour M, Breider MA. Tumor cell-enhanced sensitivity of vascular endothelial cells to photodynamic therapy. Lasers Surg Med 1994; 15: 342-350.
98. Straume O, Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003; 6: 295-301.
99. Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L, Klagsbrun M. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Mol Cancer Res 2010; 8: 1063-1073.
100. Gattoni-Celli S, Cole DJ. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol 1996; 23: 754-758.
101. Geertsen R, Hofbauer G, Kamarashev J, Yue FY, Dummer R. Immune escape mechanisms in malignant melanoma. Int J Mol Med 1999; 3: 49-57.
102. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17: 4622-4628.
103. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009; 19: 275-282.
104. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003; 88: 1772-1779.
105. Yom SS, Busch TM, Friedberg JS, et al. Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol 2003; 78: 75-81.
106. Verrico AK, Haylett AK, Moore J V. In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy. Lasers Med Sci 2001; 16: 192-198.
107. Hanlon JG, Adams K, Rainbow AJ, Gupta RS, Singh G. Induction of Hsp60 by Photofrin-mediated photodynamic therapy. J Photochem Photobiol B 2001; 64: 55-61.
108. Gomer CJ, Ferrario A, Rucker N, Wong S, Lee AS. Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization. Cancer Res 1991; 51: 6574-6579.
109. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 2005; 65: 1018-1026.
110. Nowis D, Legat M, Grzela T, et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 2006; 25: 3365-3374.
111. Henderson BW, Owczarczak B, Sweeney J, Gessner T. Effects of photodynamic treatment of platelets or endothelial cells in vitro on platelet aggregation. Photochem Photobiol 1992; 56: 513-521.
112. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 1990; 50: 2599-2603.
113. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 2006; 12: 2568-2576.
114. Jiang H, Granville DJ, North JR, Richter AM, Hunt DW. Selective action of the photosensitizer QLT0074 on activated human T lymphocytes. Photochem Photobiol 2002; 76: 224-231.
115. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299: 1033-1036.
116. Filip A, Clichici S, Daicoviciu D, et al. Chemopreventive effects of Calluna vulgaris and vitis vinifera extracts on UVB-induced skin damage in SKH-1 hairless mice. J Physiol Pharmacol 2011; 62: 385-392.
117. Marshall JF, Chan WS, Hart IR. Effect of photodynamic therapy on anti-tumor immune defenses: comparison of the photosensitizers hematoporphyrin derivative and chloro-aluminum sulfonated phthalocyanine. Photochem Photobiol 1989; 49: 627-632.
118. Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 1997; 57: 2187-2192.
119. Korbelik M, Krosl G. Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 1994; 60: 497-502.
120. Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 2002; 183: 43-51.
121. de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 1996; 56: 2908-2911.
122. Korbelik M, Cooper PD. Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin. Br J Cancer 2007; 96: 67-72.
123. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
124. Arvieux J, Yssel H, Colomb MG. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 1988; 65: 229-235.
125. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-986.
126. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006; 55: 900-909.
127. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62: 1604-1608.